Core Points - The article outlines the independent non-executive director system of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to enhance corporate governance and ensure compliance with relevant laws and regulations [1][2][3] Group 1: General Provisions - The independent non-executive director is defined as a director who does not hold any other position in the company and has no direct or indirect interests that could affect their independent judgment [1] - The independent non-executive directors are required to fulfill their duties diligently and loyally to the company and all shareholders [2] Group 2: Qualifications and Conditions - Candidates for independent non-executive directors must meet specific qualifications, including having at least five years of relevant work experience and a good personal character [6] - Individuals who have significant relationships with the company or its major shareholders are prohibited from serving as independent non-executive directors [3][4] Group 3: Nomination and Election Procedures - The nomination of independent non-executive directors can be proposed by the board or shareholders holding more than 1% of the company's issued shares [8][9] - The election of independent non-executive directors must follow a cumulative voting system if two or more are elected [6] Group 4: Responsibilities and Duties - Independent non-executive directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice to enhance decision-making [15][16] - They have the authority to independently hire external consultants for audits or inquiries [16] Group 5: Performance and Reporting - Independent non-executive directors must submit an annual report detailing their attendance at meetings and their engagement with shareholders [27][28] - The company is required to provide necessary support and resources for independent non-executive directors to perform their duties effectively [32][33] Group 6: Compensation and Insurance - The company is responsible for covering the costs incurred by independent non-executive directors when hiring professional services [36] - A compensation system for independent non-executive directors should be established and disclosed in the annual report [37]

Core Points - The document outlines the rules for the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, aiming to standardize meeting procedures and decision-making processes to enhance governance and decision-making quality [1][3][26] Group 1: Board Structure and Responsibilities - The board of directors is responsible for significant corporate actions, including capital changes, major acquisitions, and internal management structure [3][4] - The board must convene at least four regular meetings annually, with the chairman responsible for calling these meetings [7][10] - The board has the authority to decide on the appointment and remuneration of senior management, including the CEO and other executives [3][5] Group 2: Meeting Procedures - Regular meetings require a minimum of fourteen days' notice, while temporary meetings require three days' notice [11][12] - Proposals for meetings must be clear and submitted with supporting materials [9][10] - Decisions require a majority vote from the attending directors, with specific rules for handling conflicts of interest and ensuring independent director participation [20][22] Group 3: Documentation and Record-Keeping - Meeting records must include details such as date, attendees, agenda, and voting results, and should be signed by participants [23][24] - The board secretary is responsible for maintaining meeting records for ten years and ensuring they are accessible to directors upon request [26][33] - Any resolutions made must be announced according to regulatory requirements, and confidentiality must be maintained until official disclosure [29][30]

第一条 为规范上海复星医药（集团）股份有限公司（以下简称"本公司"、 "复星医药"或"上市公司"）及附属公司（以下合称"本集团"）关联交易行 为，保护本公司和全体股东的合法权益，根据《中华人民共和国公司法》、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会 （以下简称"中国证监会"）《上市公司信息披露管理办法》、《上海证券交易 所股票上市规则》（以下简称"上证所《上市规则》"）、《香港联合交易所有 限公司证券上市规则》（以下简称"联交所《上市规则》"）等法律、法规、规 章、规范性文件以及《上海复星医药（集团）股份有限公司章程》 （以下简称"《公 司章程》"）的有关规定，特制定本制度。 第二条 关联交易应当保证合法性、必要性、合理性和公允性，并保持上市 公司的独立性，不得利用关联交易调节财务指标，损害上市公司利益。 交易各方不得隐瞒关联/连关系或者采取其他手段，规避本公司的关联交易 审议程序和信息披露义务。 上海复星医药（集团）股份有限公司 关联交易管理制度 （2025年修订） 第一章 总 则 第三条 股东会、董事会应当根据本公司证券上市地监管机构以及《公司章 程》的规定对关联交易实 ...

上海复星医药（集团）股份有限公司 信息披露暂缓与豁免业务管理制度 （2025年修订） 第一条 为规范上海复星医药（集团）股份有限公司（以下简称"本公司"或 "上市公司"）信息披露暂缓与豁免行为，依法合规履行信息披露义务，保护投 资者的合法权益，根据《中华人民共和国证券法》、中国证券监督管理委员会《上 市公司信息披露暂缓与豁免管理规定》 《上海证券交易所股票上市规则》 第三条 本公司和其他信息披露义务人应当审慎确定信息披露暂缓、豁免事 项，并履行内部审核程序后方可实施。 第四条 本公司和其他信息披露义务人有确实充分的证据证明拟披露的信息 涉及国家秘密或者其他因披露可能导致违反国家保密规定、管理要求的事项（以 下统称"国家秘密"），依法豁免披露。 （以下简 称"《股票上市规则》"）、《香港联合交易所有限公司证券上市规则》（以下简称 "《香港上市规则》"）、香港《证券及期货条例》、香港证券及期货事务监察委员 会《内幕消息披露指引》 《上海复星医药（集团）股份有限公司章程》 （以下简称 "《公司章程》"）、 《上海复星医药（集团）股份有限公司信息披露制度》 （以下简 称"《信息披露制度》"）等规定，特制定本制度。 第 ...

Core Points - The document outlines the management measures for follow-up investments by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to enhance employee engagement and support strategic development [1][2] - The follow-up investment committee is established to review and approve investment proposals from subsidiaries, ensuring compliance with relevant laws and regulations [2][3] - The follow-up investment personnel include key decision-makers and core management teams from both the company and the invested projects [3][4] Chapter Summaries Chapter 1: General Principles - The purpose of the follow-up investment management measures is to regulate the procedures for follow-up investments and to promote employee innovation and entrepreneurship [1] - The term "invested enterprises/projects" refers to those deemed significant for the group's development by the follow-up investment committee [1] Chapter 2: Follow-up Investment Management Organization - A follow-up investment committee is formed, consisting of the company's executive directors and the Chief Human Resources Officer, responsible for reviewing investment proposals [2] - Subsidiaries are required to establish execution teams to handle the formulation and management of follow-up investment plans [2] Chapter 3: Scope of Follow-up Investment Personnel - The follow-up investment personnel include core decision-making teams, investment teams, and key management and employees from the invested enterprises/projects [3] Chapter 4: Forms of Follow-up Investment - Follow-up investments can be made through a designated platform or other legal forms, primarily structured as limited partnerships [4][5] Chapter 5: Follow-up Investment Contribution Methods - Contributions must be made in cash from the personal funds of the follow-up investment personnel, with no financial support from the group or invested enterprises [5][6] Chapter 6: Follow-up Investment Costs and Returns - The follow-up investment platform will bear operational costs, while individual personnel are responsible for their own expenses [6] Chapter 7: Exit Mechanism for Follow-up Investments - The follow-up investment committee has the authority to decide on exit strategies based on various scenarios, including successful listings or transfers of invested enterprises [6][7] Chapter 8: Supplementary Provisions - The board of directors is responsible for interpreting these measures, which will take effect upon approval by the shareholders' meeting [7]

上海复星医药（集团）股份有限公司 内幕信息知情人管理制度 （2025年修订） 第一章 总则 第一条 为进一步规范上海复星医药（集团）股份有限公司（以下简称"公 司"）内幕信息及内幕信息知情人的管理，维护公司信息披露的公开、公平、公 正原则，保护投资者的合法权益，根据《中华人民共和国公司法》《中华人民共 和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会（以下简 称"中国证监会"）《上市公司信息披露管理办法》《上市公司监管指引第5号 ——上市公司内幕信息知情人登记管理制度》《上海证券交易所股票上市规则》、 香港《证券及期货条例》《香港联合交易所有限公司证券上市规则》（以下简称 "联交所《上市规则》"）及《上海复星医药（集团）股份有限公司章程》（以 下简称"《公司章程》"）、《上海复星医药（集团）股份有限公司信息披露制 度》等有关规定，特制定本制度。 第二条 公司董事会（以下简称"董事会"）应当保证内幕信息知情人档案 的真实、准确和完整，并按照本制度要求及时报送。董事长为主要责任人，董事 会秘书负责办理上市公司内幕信息知情人的登记入档和报送事宜。 第二章 内幕信息及其范围 第三条 本制度所指内幕信息是 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-108 上海复星医药（集团）股份有限公司 第十届董事会第一次会议（临时会议）决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"或"公司"）第十届 董事会第一次会议（临时会议）于2025年6月24日在上海市宜山路1289号会议室以现场 与通讯（视频会议）相结合方式召开，应到会董事12人，实到会董事12人。会议由本 公司执行董事陈玉卿先生主持。本次会议的召开符合《中华人民共和国公司法》（以 下简称"《公司法》"）、其他有关法律法规和《上海复星医药（集团）股份有限公 司章程》（以下简称"《公司章程》"）的规定。会议审议并达成如下决议： 一、选举第十届董事会董事长、联席董事长、副董事长。 选举陈玉卿先生为董事长、关晓晖女士为联席董事长、文德镛先生为副董事长。 表决结果：同意 12 票，反对 0 票，弃权 0 票。 二、选举第十届董事会各专门委员会组成人员。 经董事长提名，选举产生第十届董事会各专门委员会组成人员： ...

Core Viewpoint - Fosun Pharma has completed its board of directors' re-election and appointed a new senior management team, indicating a strategic shift towards leveraging internal talent with extensive experience in the company [1][2]. Group 1: Board of Directors and Management Changes - Chen Yuqing has been appointed as the Chairman, with Guan Xiaohui as Co-Chairman and Wen Deyong as Vice Chairman [1]. - The new CEO and President, Liu Yi, will take office on June 24, 2025, alongside Co-Presidents Li Jing, Wang Xingli, and Zhang Wenjie [1]. - The majority of the new board members have long tenures within the company, showcasing a preference for internal candidates [1][2]. Group 2: Background of Key Executives - Chen Yuqing joined Fosun Pharma in January 2010 and has held various HR-related positions before becoming Co-CEO in June 2022 [1]. - Guan Xiaohui has been with the company since May 2000, previously serving as CFO and holding various leadership roles [1][2]. - Wen Deyong, who has a pharmacy background, joined Fosun Pharma in May 2002 and has held significant positions within the company [2]. Group 3: New Executive Team Profiles - Zhang Wenjie, newly appointed Executive President, was previously known for his role at Fosun Pharma's innovative drug platform, Fuhong Hanlin, and has experience in international pharmaceutical companies [3]. - Liu Yi, the current CEO, has been with the company since November 2015 and has a background in medical devices and diagnostics [3]. - Other new executives, such as Li Jing and Wang Xingli, bring solid pharmaceutical backgrounds and experience from major pharmaceutical companies [2].

EF001 第 2 頁 共 2 頁 v 1.1.1 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 上海復星醫藥（ 集團）股份有限公司 | | | 股份代號 02196 | | | 多櫃檯股份代號及貨幣 不適用 | | | 相關股份代號及名稱 不適用 | | | 公告標題 截至二零二四年十二月三十一日止年度之末期股息 | | | 公告日期 2025年6月24日 | | | 公告狀態 更新公告 | | | 更新派息金額及公司預設派發貨幣、匯率、除淨日、為符合獲取股息分派而遞交股份過 | | | 更新/撤回理由 | 戶文件之最後時限、暫停辦理股份過戶登記手續之日期、記錄日期、股息派發日、代扣 | | 所得稅信息等信息 | | | 股息信息 | | | 股息類型 末期 | | | 股息性質 普通股息 | | | 財政年末 2024年12月31日 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 於股東周年大會、2025年第一次A股類別股東會 及2025年第一次H股類別股東會所提呈決議案的投票結果 重選及選舉董事 取消監事會及監事退任 派發末期股息 及 暫停辦理H股股東名冊登記 上海復星醫藥（ 集團 ）股份有限公司（「本公司」）股東周年大會（「股東周年大會」）、2025年第 一 次 A 股 類 別 股 東 會（「 A 股 類 別 股 東 會」）及 2025 年 第 一 次 H 股 類 別 股 東 會（「 H 股 類 別 股 東 會」（）統稱「大會」）已於2025年6月24日（ 星期二 ）下午一時三十分假座中國上海市虹許路358 號上海天禧嘉福璞緹客酒店依次舉行。 茲 提 ...